Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.46 |
| ▸ | HPGD | P15428 | 7/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | CASP1 | P29466 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20199403 | 0.86 | KDM4E (0.54) | MAPTKDM4EHPGDHSD17B10CASP1 | |
| SCHEMBL21331461 | 0.82 | KDM4E (0.50) | MAPTKDM4EHPGDHSD17B10CASP1 | |
| SCHEMBL20199621 | 0.80 | DCTPP1 (0.54) | MAPTKDM4EHPGDHSD17B10CASP1 | |
| SCHEMBL30051141 | 0.80 | DCTPP1 (0.54) | MAPTKDM4EHPGDHSD17B10CASP1 | |
| SCHEMBL25151263 | 0.78 | KDM4E (0.45) | MAPTKDM4EHPGDHSD17B10TSHR | |
| SCHEMBL18003556 | 0.76 | DHODH (0.52) | MAPTKDM4EHPGDHSD17B10CASP1 | |
| SCHEMBL14734326 | 0.76 | ALDH1A1 (0.41) | MAPTKDM4EHPGDHSD17B10TSHR | |
| SCHEMBL20199459 | 0.76 | MAPT (0.44) | MAPTKDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL5089108 | 0.72 | MAPT (0.51) | MAPTKDM4ECASP1MEN1KMT2A | |
| SCHEMBL4685138 | 0.72 | FAAH (0.54) | MAPTKDM4EHPGDHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225912-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018098411-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276463-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | MAPT 81/4885KDM4E 2252/4885HPGD 2982/4885 |
| US-10774086-B2 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | MAPT 81/4885KDM4E 2252/4885HPGD 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.